Dear , Dear , Dear ,

I would like to thank you for your letter of 24 January 2018 addressed to President Juncker and Commissioner Oettinger on health and health research in the next Framework Programme for Research and Innovation and on the 10\textsuperscript{th} Anniversary celebrations of IMI to be held in Brussels in June. Please allow me to respond on their behalf.

I very much appreciate the strong commitment of the pharmaceutical industry to the EU Framework Programmes for Research and Innovation and to its collaboration with the EU in the context of the IMI public-private partnership. This partnership has already produced significant results, particular in the area of infectious diseases, in the delivery of new solutions to patients, in the development of personalised medicine, and in the digitalisation of health and care. Based on this positive experience, the precise future of public-private partnerships, including a potential successor partnership to IMI\textsuperscript{2} is still to be determined and to be agreed with the Member States and the European Parliament.

I welcome your support for a reinforced EU Research and Innovation Framework Programme in the next multiannual financial framework (MFF), in order to strengthen even further the vibrant EU research and innovation community and to increase EU competitiveness.

I would like to assure you of my highest consideration for health research and innovation, which not only drives economic growth but also contributes to better health and well-being of citizens.

Yours sincerely,

Carlos MOEDAS

Merck
European Federation of Pharmaceutical Industries and Associations (EFPIA)
UCB
EFPIA, IMI

@efpia.eu

Electronically signed on 19/04/2018 18:29 (UTC+02) in accordance with article 4 2 (Validity of electronic documents) of Commission Decision 2004/563.